Back to library

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Insulin Analog · Endocrine

Insulin Glargine (Lantus)

Long-acting basal insulin analog for type 1 and type 2 diabetes.

FDA-Approved

Plain-Language Label Highlights

Brand names: Lantus, Basaglar, Toujeo, Semglee

What it's approved for

Type 1 and type 2 diabetes — once-daily basal insulin.

A long-acting insulin that gives you a flat, ~24-hour background level of insulin between meals and overnight.

Common side effects
  • Low blood sugar (hypoglycemia)
  • Weight gain
  • Injection-site reactions
  • Lipohypertrophy
Serious risks to know
  • Severe hypoglycemia
  • Severe allergic reactions
  • Low potassium
  • Fluid retention/heart failure with TZDs
Who should avoid or use with extra caution
  • Active hypoglycemia
  • Known insulin glargine hypersensitivity

Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.

Mechanism of Action

Recombinant human insulin analog with two arginine residues added to the B-chain and asparagine→glycine at A21, forming microprecipitates at injection site for ~24-hour glucose-lowering activity via insulin receptor activation.

Research Areas

Type 1 diabetes basal coverage
Type 2 diabetes basal insulin therapy
Gestational diabetes

Common Research Protocols

Once-daily SC

Subcutaneous injection once daily at the same time, titrated to fasting glucose.

Protocols summarized for educational reference from published research. Not dosing guidance.

Cited Research

[1]Diabetes Care·2003

Treat-to-target insulin glargine trials

Established efficacy and lower nocturnal hypoglycemia vs NPH insulin.

Important Considerations

  • FDA-approved.
  • Hypoglycemia and weight gain are primary risks.
  • Do not mix with other insulins.

Explore more peptides

Educational Information Only — Not Medical Advice

All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.

Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.

Searching the library…

Ask the Library

Ask anything about peptides — answers come from our curated reference library with citations.

Find a pharmacy that carries Insulin Glargine (Lantus)

Leave your details and a vetted partner pharmacy will reach out with availability and pricing.